ADAM17 flox/flox (f/f) mice, a kind gift from Carl Blobel (NY), 19 and α-myosin heavy chain (α-MHC)-Cre (Cre) mice (Jackson Laboratories) were crossbred to generate cardiomyocyte-specific ADAM17 knockdown (ADAM17 flox/flox /α-MHC-Cre or f/f/Cre) and the littermate controls (ADAM17 flox/flox or f/f). MI induction and echochardiography were conducted as before. [20] [21] [22] All experiments were conducted in accordance with the guidelines of the University of Alberta Animal Care and Use Committee and the Canadian Council of Animal Care.
Immunohistochemistry was used to detect CD31, 21 phosphovascular endothelial growth factor receptor 2 (VEGFR2; Tyr1175), ADAM17, 23 neutrophil, and macrophage 20 as before. Lectin immunofluorescence assay using fluorescein-conjugated Ricinus communis agglutinin I (lectin; Vectorlabs) perfusion method was used to assess microvascular density in sham and MI heart. 21 mRNA expression analyses were performed by Taqman reverse transcription polymerase chain reaction as before. 20, 24, 25 Electrophoretic mobility shift assay was used to detect DNA-nuclear factor-κB (NFκB) interaction using the LightShift chemiluminescent electrophoretic mobility shift assay kit (Thermo Scientific) according to the manufacturer's instructions. ELISA was used to detect VEGF A and TNFα levels.
Ex vivo ischemia reperfusion of isolated hearts was performed as before. 22 In vitro cocultures of adult cardiomyocyte and adult cardiofibroblast (cMyo-cFB) cocultures were generated as before. 25 In vitro gene silencing was achieved by transfection with Silencer Select Negative Control-siRNA (Life Technologies) or Silencer Select ADAM17 siRNA (Life Technologies) using Lipofectamine RNAiMAX Transfection Reagent (Life Technologies) according to the manufacturer's instructions.
Statistical Analyses
All statistical analyses were performed using the IBM SPSS Statistics 19 software. Mortality and rupture incidents were compared using the Kaplan-Meier survival curve followed by the Logrank test. data. Two-way ANOVA was used for comparison among groups to determine significant differences between the 2 factors (MI and genotype; or ischemia and ADAM17-siRNA) and the interaction between these 2 factors. Multiple comparisons within the same genotype involved 1-way ANOVA followed by Bonferroni test. Student t test was used when comparing only 2 groups. Statistical significance was recognized at P<0.05.
Results

ADAM17 Knockdown Exacerbates Cardiomyopathy After MI
We first examined how ADAM17 levels are altered in the myocardial tissue after MI. In the nonischemic myocardium, ADAM17 was detected primarily but not limited to the membrane of cardiomyocytes as it overlapped with wheat germ agglutinin membrane staining. However, dispersed distribution was observed in the infarct and periinfarct myocardium ( Figure After MI, f/f/Cre mice showed compromised survival rate (35.5% versus 65.2% in f/f mice) and higher cardiac rupture incidence (55.8% versus 27.3% in f/f mice; Figure IAi and IAii in the Data Supplement). However, the infarct size was comparable between the 2 genotypes at 1 week post MI ( Figure 1B ). Heart function measured by echocardiography showed similar cardiac dysfunction and left ventricular dilation between genotypes at 3 days post MI ( Figure III (375±21 bpm in f/f/Cre versus 387±13 bpm in f/f). ADAM17 mRNA was significantly reduced post MI in both genotypes but to a greater extent in f/f/Cre hearts (Figure 1Di ). Other ADAMs were altered similarly between the 2 genotypes post MI including increased ADAM9 in the infarct, reduced ADAM10 in the peri-and noninfarct, and elevated ADAM12 in the infarct and peri-infarct myocardium (Figure 1Dii-1Div ).
ADAM17 Deficiency Suppresses Post-MI Angiogenesis But Does Not Alter Inflammation
To determine the mechanism underlying the exacerbated post-MI recovery in f/f/Cre mice, we first examined whether ADAM17 knockdown hearts are more susceptible to ischemic injury. Using the isolated heart Langendroff ischemia-reperfusion model, we found that both genotypes showed comparable rate and amplitude of recovery after a 30-minute ischemic period during reperfusion ( Figure IV in the Data Supplement). Therefore, ADAM17 deficiency does not enhance acute susceptibility to ischemia or ischemia-reperfusion injury in the isolated heart ex vivo, as such, the adverse post-MI events in f/f/Cre mice are related to the myocardial response in vivo.
Among the systemic events, angiogenesis and inflammation are critical in influencing post-MI myocardial repair and remodeling. We assessed the vascular density in the infarct and peri-infarct myocardium using fluorescent-labeled lectin perfusion (whole animal) and CD31-staining. Although vascular density was found to be reduced after MI in both genotypes, this reduction was significantly greater in the infarct myocardium of f/f/Cre hearts compared with f/f mice at 1 week post MI (Figure 2A and 2B ). Myocardial vascular density in sham-operated f/f/Cre mice was comparable with f/f mice. Inflammation is an early post-MI response that can influence the fate of cardiomyocytes and infarct expansion. 26 Assessment of the infiltrating inflammatory cells at 3 days post MI showed similar densities of neutrophils (A) and macrophages (B) in the infarct and peri-infarct regions of both genotypes (Figure 3 ).
ADAM17 Regulates Post-MI Angiogenesis Through Induction of VEGFR2
Angiogenesis is mediated through activation of VEGFR2 by its primary ligand, VEGF A , which is then phosphorylated (p-VEGFR2) and translocated to the nucleus. 27 f/f/Cre Consistent with the lower vascular density in f/f/Cre-MI hearts, p-VEGFR2 density was markedly reduced in the infarct myocardium of these mice compared with f/f-MI mice ( Figure 4A ). Superimposing the p-VEGFR2 and lectin staining revealed that p-VEGFR2 detection was not limited to the endothelial cells in the vascular wall within the infarct and peri-infarct areas ( Figure V in the Data Supplement). Furthermore, total VEGFR2 protein ( Figure 4B ) and mRNA expression ( Figure 4C ) were also significantly reduced in f/f/Cre hearts post MI. Activation of NFκB has been reported to induce VEGFR2 gene expression. 28 Among the substrates shed by ADAM17, TNF-α activates TNF-α receptor 1, and triggers nuclear translocation of NFκB. 29 We performed electrophoretic mobility shift assay to detect nuclear translocation and DNA binding of NFκB and found that the NFκB-DNA binding was indeed suppressed in the f/f/Cre compared with f/f hearts within 3 hours of MI (Figure 4D) . Consistently, TNF-α levels in the myocardial tissue (i) and serum (ii) were lower in the f/f/Cre-MI mice at this time point ( Figure 4E ). These data collectively suggest 
Proteolytic Activities Are Not Altered With ADAM17 Downregulation After MI
The extracellular matrix and its remodeling are major contributors to post-MI remodeling and tissue angiogenesis. As such, we investigated whether the reduced angiogenesis in ADAM17-knockdown hearts was associated with altered levels or activity of the proteolytic enzymes that regulated extracellular matrix turnover, the matrix metalloproteinases (MMPs), or their inhibitors, tissue inhibitor of metalloproteinases (TIMPs). Expression analysis of MMPs, including the gelatinases, MMP2 and -9; stromelysins, MMP3, -10 and -11; collagenases MMP-13 and MT1-MMP (MMP14), MT2-MMP (MMP15), and MMP28 showed that MMP3 was increased to a greater degree in the infarct region of f/f/Cre hearts, whereas the increase in MMP9 and MMP10 did not reach statistical significance compared with f/f-MI hearts (Figure 5Aii-5Aiv ).
Meanwhile, mRNA expressions of other MMPs were altered similarly in both genotypes after MI ( Figure 5A ). Expression of TIMPs ( Figure 5B ) showed that the rise in TIMP2 in the infarct region of f/f hearts was not matched by a similar change in f/f/Cre hearts (ii), whereas TIMP3 levels were reduced in f/f/Cre hearts post MI (iii). Measurement of total proteolytic activities showed a similar rise in collagenase (i) and gelatinase (ii) activities post MI ( Figure 5C ). Therefore, reduced ADAM17 levels did not alter proteolytic activities in the myocardium post MI.
ADAM17 Silencing Reduced VEGFR2 Expression But Not VEGF A Bioavailability In Vitro
To further confirm the role of ADAM17 in VEGFR2 expression under ischemic conditions and to also examine whether the reduced VEGFR2 activation could be because of reduced VEGF A bioavailability in the absence of ADAM17 sheddase activities, we generated cocultures of adult cMyo and cFB (to simulate the in vivo myocardial scenario where these cell types interact) and used ADAM17-small interfering RNA (ADAM17-siRNA) to inactivate ADAM17. ADAM17-siRNA reduced ADAM17 mRNA and protein levels by ≈86% compared with negative control-siRNA ( Figure VIA in the Data Supplement). Specificity for the siRNA system was confirmed by unaltered levels of other ADAMs (ADAM9, -10, and -12; Figure IVB in the Data Supplement). To exclude the compensatory contribution of the ADAM17 from cFB, ADAM17-siRNA-treated cFBs were cocultured with cMyo from f/f/ Cre mice and, subsequently, subjected to ischemic conditions. Ischemia triggered mRNA expression of VEGFR2 in control cocultures (normal ADAM17 levels), but this increase was suppressed in ADAM17-deficient cocultures (Figure 6Ai ). Expression of VEGFR1 and VEGF A were induced similarly by ischemia and not altered after ADAM17 silencing (Figure 6Aii and 6Aiii ). In addition, ADAM17 silencing did not alter the ischemia-induced VEGF A shedding into the conditioned media ( Figure 6B ). These data suggest that the primary effect of ADAM17 under ischemic conditions is through regulation of VEGFR2 expression rather than enhancing bioavailability of VEGF A. Figure 6 . Targeted A disintegrin and metalloproteinase 17 (ADAM17) silencing in cocultured cardiomyocyte-cardiofibroblast in vitro suppressed ischemia-induced rise in vascular endothelial growth factor receptor 2 (VEGFR2) mRNA levels. A, mRNA levels of VEGF receptors, VEGFR1 and VEGFR2, and VEGF A in cocultured adult cardiomyocyte-cardiofibroblasts transfected with ADAM17-siRNA (or negative siRNA control), and subjected to ischemia. B, VEGF A protein levels shed into the conditioned media. n=6 per group; 3 independent cultures from 3 individual hearts; 2-way ANOVA. Significant differences were detected for one factor (ischemia) and its interaction with ADAM17-siRNA (Ai), for ischemia only (Aii and B) , for both factors (ischemia and ADAM17-siRNA) and their interaction (Aiii). *P<0.05 vs corresponding nonischemic condition and P<0.05 vs corresponding (negative) siRNA control. HPRT indicates hypoxanthine phosphoribosyltransferase; and RFU, relative fluorescence units.
Discussion
ADAM17 is a membrane-bound enzyme that can mediate catalytic shedding of many growth factors and cytokines, and it has been correlated with adverse outcomes in cardiomyopathies. 4, [6] [7] [8] [9] [10] In this study, we demonstrate the key role of cardiomyocyte ADAM17 in post-MI remodeling and recovery. ADAM17 knockdown in cardiomyocytes was sufficient to suppress VEGFR2 induction and activation, impairing angiogenesis in the infarct and peri-infarct myocardium, leading to exacerbated left ventricular dilation and dysfunction. The role of endothelial ADAM17 in angiogenesis has been reported in the retina through enhanced VEGF A shedding and bioavailability. 17 In this study, we report the significance of cardiomyocyte ADAM17 in regulating postischemic angiogenesis by regulating VEGFR2 transcription and activation independent from VEGF A bioavailability.
Angiogenesis has the potential to rescue the ischemic myocardium at early stages after MI and can prevent the transition to heart failure. 11, 12 ADAM17, particularly in endothelial cells, has been shown to promote angiogenesis through different mechanisms. 16, 17, 30, 31 In this study, we examined the contribution of cardiomyocyte ADAM17 in post-MI repair and found that reduced ADAM17 in cardiomyocytes suppresses ischemia-induced angiogenesis leading to exacerbation of cardiac dysfunction and dilation. In attempting to identify the cell types that exhibit VEGFR2 activation within the infarct region, we found that although a fraction of the p-VEGFR2positive cells colocalized with endothelial (lectin-positive) cells, p-VEGFR2 was also detected in nonendothelial cells. It is highly unlikely that these cells are inflammatory cells because by 1 week post MI, inflammatory cells have already dissipated, and at this time point, the infarct region is devoid of cardiomyocytes. It has been reported that vascular trauma can mobilize bone marrow endothelial progenitor cells (with limited CD31 expression) into the peripheral circulation to enhance angiogenesis. 32 VEGFR2-positive cardiomyocyte progenitor cells have also been reported to contribute to the formation of the cardiomyocytes and endothelial cells. 33 It is plausible that after tissue injury, as a part of recapitulation of fetal gene expression pattern, such progenitor cells are migrated to and proliferated within the damaged myocardium to promote tissue repair.
MMPs and the overall proteolytic activities can regulate extracellular matrix remodeling and can thereby contribute to angiogenesis. However, ADAM17 knockdown did not alter the proteolytic activities in the myocardium post MI. TIMP3 has been reported to be the physiological inhibitor of ADAM17. 34 Reduced TIMP3 levels in the f/f/Cre hearts may be balanced by the reduced ADAM17 levels in these hearts.
ADAM17, also known as TNF-α-converting enzyme, can shed the membrane-bound TNF-α 1 and generate soluble/ activate TNF-α that then binds to and activates TNF-α receptor-1 and the downstream signaling pathways, mainly the NFκB pathway. 35 Activation of NFκB can induce VEGFR2 expression via complement 32. 28 We found that ADAM17 knockdown led to reduced TNF-α levels and NFκB-DNA binding post MI, which could underlie the reduced VEGFR2 expression in f/f/Cre-MI hearts. In addition to NFκB-binding elements, there are other potential cis-acting sequences in the VEGFR2 promoter, such as Sp-1-and Ap-2-binding sites. 36 Whether these transcription factors are also involved in the regulation of VEGFR2 expression post MI will require further investigation. It has been reported that p-VEGFR2 can bind to the Sp-1 responsive element of its promoter and upregulates its own expression through a positive feedback mechanism. 27 ADAM17 is responsible for ectodomain shedding of multiple transmembrane molecules. In addition to TNF-α and VEGF, ADAM17 can also mediate shedding of many EGFR ligands, including HB-EGF and transforming growth factor-α, 37 adhesion molecules, and some receptors of these ligands, such as TNF-α receptor-1, VEGFR2, 31 and transforming growth factor-β receptor-1. 38 Because shedding of the receptors will result in the opposite outcome of ligand shedding, the role of ADAM17 in mediating cellular events can be variable and unpredictable. Activation of EGFR leads to cell proliferation and hypertrophy, but these phenotypes were unaltered in ADAM17-knockdown mice post MI, and as such, we did not pursue this pathway further. Meanwhile, ADAM17-mediated shedding of VEGF A and the resulting activation of VEGFR2 could have provided an alternative explanation for the differential angiogenesis observed in f/f/ Cre mice after MI. We found that the role of ADAM17 in post-MI angiogensis is primarily through expression and activation of VEGFR2 rather than shedding of VEGF A .
In conclusion, this study provides the first evidence for the role of cardiomyocyte ADAM17 in post-MI angiogenesis through induction of VEGFR2. Considering the critical effect of angiogenesis in ischemic myocardium, intact levels of ADAM17 are essential for optimal post-MI remodeling. In addition, although ADAM17 overexpression has been reported to promote angiogenesis in the brain, 16 considering the broad spectrum of ADAM17 substrates, excess overexpression of ADAM17 could also result in adverse effects, and therefore, a physiological balance should be targeted to achieve optimal outcomes.
Limitations
This study provides evidence on the adverse outcomes of reduced cardiomyocyte ADAM17 on cardiac structure and function early post MI; however, the long-term effects of ADAM17 downregulation will require further investigation. Our in vitro coculture system of cMYO and cFB confirms that under ischemic conditions, ADAM17 regulates the expression of VEGFR2 but not shedding of VEGF A . However, the absence of endothelial cells in this coculture system may pose a limitation in directly extending these findings to the angiogenic events in vivo.
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